Engineered immune cells take on Hard-to-Treat cancers in early trial
NCT ID NCT05539430
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults with advanced stomach, gastroesophageal junction, esophageal, or pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to check the safety of the treatment and find the best dose to use in future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LB1908 (a type of CAR T-cell therapy that targets claudin 18.2 on cancer cells)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced stomach, esophageal, or pancreatic cancers that have not responded to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 56 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors or improve survival, and there are risks of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27705, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
John Theurer Cancer Center at HackensackUMC
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication